Immuron (ASX:IMC) Targets Growth Through Commercial and Clinical Expansion

Key Highlights

• Immuron is focusing on expanding OTC product sales and pursuing strategic partnering opportunities for its late-stage clinical assets.
• The company reported global sales revenue of AUD 5.7 million year-to-date in FY26, as of March 2026, up 7% on the prior corresponding period.
• Travelan® sales in Australia rose 15% during the third quarter of FY26.
• The company is pursuing partnering opportunities for IMM-124E and IMM-529 to reduce development funding requirements.
• IMM-529 remains Phase 2-ready following U.S. FDA investigational new drug application approval.

Immuron Limited (ASX:IMC) (NASDAQ:IMRN) has been sharpening its focus on commercial growth and strategic partnering opportunities, as the biotechnology company works toward establishing a clearer pathway to long-term profitability. The company’s evolving strategy combines revenue generation from its over-the-counter gastrointestinal health products with the potential monetisation of its late-stage clinical assets through external partnerships.

Amid growing global interest in gastrointestinal health, infectious disease prevention, and microbiome-related therapies, Immuron continues to focus on expanding its commercial and clinical-stage programs. Immuron’s core technology platform, based on orally delivered polyclonal antibodies derived from hyper-immune bovine colostrum, remains central to both its commercial and development-stage programs.

Commercial Growth Continues

Immuron currently markets two commercial products — Travelan® for travelers’ diarrhea and ProIBS® for irritable bowel syndrome — both of which form part of the company’s broader gastrointestinal health strategy.

Immuron reported global sales revenue of AUD 1.5 million during the third quarter of FY26, representing a 16% increase on the prior corresponding period. Year-to-date global sales revenue reached AUD 5.7 million, up 7% from the previous year.

Focus on Strategic Partnerships

A major part of Immuron’s current strategy involves progressing discussions around the partnering of its clinical-stage assets IMM-124E and IMM-529 for development and commercialisation.

IMM-124E, which underpins Travelan®, is eligible for an end-of-Phase 2 meeting with the U.S. FDA for the indication of travelers’ diarrhea. According to estimates referenced by the company from Lumanity, the asset carries potential peak U.S. sales of approximately US$102 million.

Meanwhile, IMM-529 has already received investigational new drug approval from the U.S. FDA and is prepared to enter Phase 2 clinical trials targeting recurrent Clostridioides difficile infection (CDI). Lumanity estimates cited by Immuron place the potential peak U.S. sales opportunity for IMM-529 at approximately US$400 million.

Under the proposed partnering model, external licensees would typically fund development, registration, and commercialization activities while providing Immuron with licensing fees, milestone payments, and royalties. The company believes this approach could reduce uncertainty around clinical funding requirements while potentially accelerating monetisation opportunities.

Addressing Large Market Opportunities

Immuron continues to frame both Travelan® and IMM-529 around large global market opportunities.

The company estimates the global travelers’ diarrhea treatment and prevention market could reach approximately US$3.31 billion in 2026. Immuron’s strategy focuses particularly on travelers visiting high-risk destinations who seek preventative and over-the-counter solutions rather than acute treatments after infection.

For IMM-529, the target market includes recurrent CDI patients. The disease remains one of the leading healthcare-associated infections in the United States, with around 400,000 cases and 30,000 deaths annually according to information cited by the company.

Immuron noted that current antibiotic treatments can disrupt the gut microbiome and leave patients vulnerable to recurrent infection, creating a potential opportunity for alternative adjunctive therapies such as IMM-529.

Outlook

Immuron stated that its existing cash balance is sufficient to fund ongoing commercial operations for Travelan® and PROIBS®. The company also expects continued year-on-year sales growth while progressing toward EBITDX breakeven excluding research and development income and expenses.

Looking ahead, Immuron expects partnering discussions for both IMM-529 and Travelan® to progress during the first half of 2027, while continuing to evaluate opportunities to expand distribution and add complementary products to its over-the-counter portfolio.

IMC shares traded at AUD 0.027, up around 4%, at the time of writing on 08 May 2026.